Author's posts
Scientists See Progress In Treatment Of COVID-19
A group of Hong Kong Physicians report in Lancet that a cocktail of drugs approved for the treatment of other viral diseases significantly improved the clinical and laboratory outcomes of hospitalized COVID-19 patients.
Putting COVID-19 Behind Us: A Research Agenda To Prepare For The Next Pandemic
COVID-19 is neither the first nor the last epidemic our country face — what do we need to do today to prepare for the next one?
Blood Clotting And COVID-19: How Serious Is It?
Anecdotal evidence suggests SARS-CoV-2 infection can lead to serious blood clots in COVID-19 patients as well as those who are otherwise asymptomatic.
Responsible Reopening: A Lesson From NYU Shanghai
The small university is taking a “try it and see” approach. If infection rates rise again, they are prepared to quickly implement harsher measures to reduce them.
COVID Immunity: How Protected Are You?
If I have antibodies to the COVID-19 virus, or if I recovered from the disease, am I protected? These are the two burning questions workers and employers are asking today.
Remdesivir: A Non-Antiviral Antiviral Drug?
The antiviral drug remdesivir is supposed to stop SARS-CoV-2 from replicating, but a recent study published in the Lancet suggests it may not be working the way it is supposed to.
Urging Caution On Remdesivir
While there is much excitement around the potential of remdesivir to treat Covid-19, the data to date is unclear as to how well the drug might work and the risk to patients who are given it.
Reducing The Risk Of In Flight COVID-19 Transmission
Contagion while flying is nothing new, even for the coronavirus. Transmission in flight of the SARS virus has been studied in detail. What have airlines done since? Precious little.
A Letter To Congress: Four Principles For A Safe Economic Reopening
A bipartisan group of public health leaders argues that the key to reopening our post-COVID economy would be to test, trace and self-isolate.
A Vaccine Candidate Protects Non-Human Primates From SARS-CoV-2 Infection
A new candidate vaccine for SARS-CoV-2 moves to human trials. Beijing based biotechnology company company, Sinovac, describes protection of macaque monkeys from infection by SARS-CoV-2 by the vaccine candidate.
